Strides Pharma Science Limited (BOM:532531)

Market Cap	62.77B
Revenue (ttm)	45.79B
Net Income (ttm)	35.29B
Shares Out	n/a
EPS (ttm)	383.79
PE Ratio	1.78
Forward PE	n/a
Dividend	864.00 (132.84%)
Ex-Dividend Date	Dec 6, 2024

Volume	31,186
Average Volume	27,588
Open	644.75
Previous Close	642.05
Day's Range	630.20 - 659.35
52-Week Range	530.70 - 1,675.25
Beta	n/a
RSI	56.54
Earnings Date	May 23, 2025

About Strides Pharma Science

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 3,065
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532531

Financial Performance

In 2023, Strides Pharma Science's revenue was 40.51 billion, an increase of 9.83% compared to the previous year's 36.88 billion. Losses were -706.14 million, -65.15% less than in 2022.